Skip to main content
. 2021 May 10;48(e1):e44–e52. doi: 10.1136/bmjsrh-2020-200955

Table 4.

Women’s experience interacting with the patent medicine vendor (PMV) by type of service received from PMV

Experience Abortion (n=193) Post-abortion care (n=67) Total (n=260) P value
n (%) n (%) n (%)
Counselled on different treatment options 159 (82.4) 48 (71.6) 207 (79.6) 0.06
Asked about questions or concerns 182 (94.3) 52 (77.6) 234 (90) <0.001
Given sufficient information about care 191 (99) 67 (100) 258 (99.2) 1
Given pain medication 181 (93.8) 64 (95.5) 245 (94.2) 0.766
Type of pain medication received 0.055
 Oral NSAID 144 (79.6) 60 (93.8) 204 (83.3)
 Oral paracetamol 8 (4.4) 1 (1.6) 9 (3.7)
 Intramuscular injection 18 (9.9) 3 (4.7) 21 (8.6)
 Other 11 (6.1) 0 (0) 11 (4.5)
Informed about follow-up care 187 (96.9) 67 (100) 254 (97.7) 0.343
Informed about when additional care required 179 (92.7) 67 (100) 246 (94.60 0.024
Informed about risk of pregnancy post-abortion 185 (95.5) 66 (98.5) 251 (96.5) 0.454
Felt services were private 188 (97.4) 67 (100) 255 (98.1) 0.332
Services well explained 193 (100) 67 (100) 260 (100)
Allowed to express concerns 192 (95.5) 65 (97) 257 (98.8) 0.172
PMV was welcoming 193 (100) 67 (100) 260 (100)
Treated in non-judgmental way 188 (97.4) 67 (100) 255 (98.1) 0.413
Mean cost of service (Nigerian Naira) among clients who paid for service (SD) (range) 2113 (1590) (1–15,000) 1348 (642) (1450–3000) 1967 (1487) (1–15,000) 0.002
 No payment 11 (5.7) 24 (35.8) 35 (13.5)
Perceived affordability of service among clients who paid for service 0.149
 Affordable 156 85.7 33 (76.7) 189 (84)
 Cost too much 26 (14.3) 10 (23.3) 36 (16)
Reside in same community as PMV shop 145 (75.1) 56 (83.6) 201 (77.3) 0.155
Counselled on contraception 186 (96.4) 64 (95.5) 250 (96.2) 0.721
Methods counselled on*
 Condoms 139 (72) 52 (77.6) 191 (73.5) 0.372
 Pills 152 (78.8) 54 (80.6) 206 (79.2) 0.749
 DMPA 159 (82.4) 57 (85.1) 216 (83.1) 0.613
 IUCD 151 (78.2) 55 (82.1) 206 (79.2) 0.503
 Implant 154 (79.8) 51 (76.1) 205 (78.8) 0.526
 Female sterilisation 35 (18.1) 26 (38.8) 61 (23.5) 0.001
 Periodic abstinence/withdrawl 47 (24.4) 28 (41.8) 75 (28.8) 0.007
Felt coerced to accept a method 14 (13.3) 8 (21.1) 22 (15.4) 0.258
Received a contraceptive method 105 (54.4) 38 (56.7) 143 (55.6) 0.743
Method received
 Condoms 18 (17.1) 6 (15.8) 24 (16.8)
 Pills 18 (17.1) 11 (28.9) 29 (20.3)
 Injection/Depo-Provera 45 (42.9) 11 (28.9) 56 (39.2)
 IUCD 8 (7.6) 3 (7.9) 11 (7.7)
 Implant 15 (14.3) 7 (18.4) 22 (15.4)
Learnt about new contraceptive method from PMV† 107 (55.4) 48 (71.6) 155 (59.6) 0.02
Would return to PMV for future services 192 (99.5) 67 (100) 259 (99.6) 0.555
Would recommend PMV to family or friends 193 (100) 67 (100) 260 (100)
Degree of satisfaction
 Very satisfied 166 (86) 47 (70.1) 213 (81.9) 0.005
 Mostly satisfied 25 (13) 20 (29.9) 45 (17.3)
 Somewhat satisfied 2 (1) 0 (0) 2 (0.8)
 Not at all satisfied 0 (0) 0 (0) 0 (0)

*Multiple response question.

†A new method refers to any modern contraceptive method previously unknown to the client.

DMPA, depot medroxyprogesterone acetate; IUCD, intrauterine contraceptive device; NSAID, non-steroidal anti-inflammatory drug; PMV, patent medicine vendor.